These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 565520)

  • 1. Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712.
    Vigouret JM; Bürki HR; Jaton AL; Züger PE; Loew DM
    Pharmacology; 1978; 16 Suppl 1():156-73. PubMed ID: 565520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine.
    Loew DM; Jaton AL; Vigouret JM
    Postgrad Med J; 1976; 52suppl 1():40-46. PubMed ID: 822407
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of the central effects of ergot alkaloids by means of electroencephalography.
    Longo VG; Loizzo A
    Pharmacology; 1978; 16 Suppl 1():189-92. PubMed ID: 643900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine, dihydroergotoxine and sleep in rats: effects of repeated administration.
    Radulovacki M; Brodie M; Walovitch R; Yanik G
    Gerontology; 1981; 27(3):152-7. PubMed ID: 7239174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central monoamine synapses as sites of action for ergot drugs.
    Fuxe K; Ogren SO; Agnati LF; Andersson K; Hall H; Köhler C; Fredholm B
    Adv Biochem Psychopharmacol; 1980; 23():41-62. PubMed ID: 6104914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromocriptine, dihydroergotoxine, methysergide, d-LSD, CF25--397, and 29--712: effects on the metabolism of the biogenic amines in the brain of the rat.
    Bürki HR; Asper H; Ruch W; Züger PE
    Psychopharmacology (Berl); 1978 May; 57(3):227-37. PubMed ID: 97702
    [No Abstract]   [Full Text] [Related]  

  • 7. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.
    Lew JY; Hata F; Ohashi T; Goldstein M
    J Neural Transm; 1977; 41(2-3):109-21. PubMed ID: 21229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions.
    Markstein R
    J Neural Transm; 1981; 51(1-2):39-59. PubMed ID: 6267192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropharmacology of bromocriptine and dihydroergotoxine (hydergine).
    Loew DM; Vigouret JM; Jaton A
    Adv Biochem Psychopharmacol; 1980; 23():63-74. PubMed ID: 6104915
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacological and biochemical evidence for the dopamine agonistic effect of bromocriptine.
    Fuxe K; Fredholm BB; Ogren SO; Agnati LF; Hökfelt T; Gustafsson JA
    Acta Endocrinol Suppl (Copenh); 1978; 216():27-56. PubMed ID: 347864
    [No Abstract]   [Full Text] [Related]  

  • 11. New central dopamine agonists.
    Borsy J
    Pol J Pharmacol Pharm; 1985; 37(3):227-36. PubMed ID: 2999737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile.
    Silbergeld EK; Pfeiffer RF
    J Neurochem; 1977 Jun; 28(6):1323-6. PubMed ID: 577501
    [No Abstract]   [Full Text] [Related]  

  • 13. Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis.
    Fuxe K; Fredholm BB; Ogren SO; Agnati LF; Hökfelt T; Gustafsson JA
    Fed Proc; 1978 Jun; 37(8):2181-91. PubMed ID: 350633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover.
    Snider SR; Hutt C; Stein B; Prasad AL; Fahn S
    J Pharm Pharmacol; 1976 Jul; 28(7):563-6. PubMed ID: 8610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptin and methylergometrine: pharmacological approach of the mechanism of their central effects.
    Puech AJ; Simon P; Chermat R; Boissier JR
    Pharmacol Res Commun; 1977 Mar; 9(3):299-306. PubMed ID: 577309
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of dihydroergotoxine, bromocriptine, and ergotamine on penile erection in Wistar rats.
    Radosavljevic M; Pajovic B; Radunovic M; Radojevic N; Bjelogrlic B
    J Androl; 2012; 33(5):866-71. PubMed ID: 22441761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior.
    Clemens JA; Okimura T; Smalstig EB
    Arzneimittelforschung; 1993 Mar; 43(3):281-6. PubMed ID: 8489554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dihydrogenated ergot alkaloids on the sleep-wakefulness cycle and on brain biogenic amines in the rat.
    Loew DM; Depoortere H; Buerki HR
    Arzneimittelforschung; 1976; 26(6):1080-3. PubMed ID: 822856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromocriptine: a rather specific stimulant of dopamine receptors regulating dopamine metabolism.
    Di Chiara G; Vargiu L; Porceddu ML; Gessa GL
    Adv Biochem Psychopharmacol; 1977; 16():443-6. PubMed ID: 578073
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of apomorphine, bromocriptine and Sandoz CM 29-712 (6-methyl-8a-cyanomethyl-ergoline-l) in four different turning models in the rat [proceedings].
    Jaton AL; Loew DM; Vigouret JM
    Br J Pharmacol; 1978 Mar; 62(3):395P. PubMed ID: 565235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.